1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd.

SHTDF
Sinopharm Group Co. Ltd.US flagOther OTC
2.13
USD
- -
- -
6.65BMarket Cap
Sinopharm Group Co. Ltd.
SHTDF
(Other OTC)

Recent

price

2.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
30.57
43.39
56.81
66.13
77.41
82.63
93.53
103.75
116.09
143.11
146.7
167.48
176.93
191.17
187.3
184.31
46.96
Revenue per Share
0.53
0.66
0.82
0.89
1.11
1.36
1.68
1.88
1.97
2.1
2.31
2.49
2.73
2.9
2.26
2.29
0.65
Basic EPS, GAAP
-0.12
-0.05
0.97
1.44
1.42
4.38
2.86
0.32
0.08
5.46
2.91
2.27
5.94
4.75
3.07
4.01
-0.42
Free Cash Flow per Basic Share
0.01
0.17
0.19
0.25
0.26
0.31
0.41
0.47
0.53
0.59
0.6
0.69
0.75
0.82
0.87
0.68
- -
Dividend per Share
1
1.02
1
3.12
1.07
4.63
5.87
0.93
1
1
1
1
14.75
16.83
18.22
19.84
17.34
Book Value per Share
5.5
6.68
7.24
9.12
11.58
12.34
13.86
17.1
20.48
22.26
24.87
28.11
31.42
34.7
37.08
39.74
36.38
Tangible Book Value per Share
2,265
2,356
2,403
2,523
2,585
2,767
2,760
2,965
2,968
2,972
3,111
3,111
3,121
3,121
3,121
3,121
3,087
Basic Weighted Avg Shares
69,234
102,225
136,502
166,866
200,131
228,633
258,117
307,666
344,526
425,273
456,415
521,051
552,148
596,570
584,508
575,168
144,969
Sales/Revenue/Turnover
3.48
3.56
3.57
3.66
3.93
4.02
3.85
4.05
4.57
4.35
4.33
4.03
4.08
3.73
3.04
2.97
3.46
Operating Margin (%)
301
460
567
677
835
1,006
1,068
1,240
1,395
3,114
3,597
3,922
4,165
4,430
4,734
4,289
- -
Depreciation Expense
1,209
1,561
1,979
2,250
2,875
3,772
4,647
5,576
5,836
6,253
7,187
7,759
8,526
9,054
7,050
7,155
1,992
Net Income, GAAP
23.67
23.18
23.28
22.53
23.3
23.14
22.78
22.82
22.96
22.82
22.44
23.16
22.72
23.07
25.55
26.79
23.72
Effective Tax Rate (%)
1.75
1.53
1.45
1.35
1.44
1.65
1.8
1.81
1.69
1.47
1.57
1.49
1.54
1.52
1.21
1.24
1.37
Profit Margin (%)
9,109
15,942
16,111
18,872
24,253
22,278
33,022
38,188
44,580
51,575
63,633
71,616
84,443
95,344
97,072
100,070
99,125
Working Capital
91
5,182
5,192
4,134
4,223
608
11,135
5,594
5,019
11,470
12,162
11,669
14,957
17,255
11,897
6,141
19,606
LT Debt
14,719
20,388
22,949
28,611
36,290
40,879
44,532
57,947
68,276
76,939
89,947
99,654
110,069
120,319
126,687
134,160
122,433
Total Equity
10.74
10.51
10.03
10.04
9.96
10.35
10.29
10.91
10.92
10.99
10.39
9.72
9.84
9.02
6.57
6.05
- -
Return on Invested Capital (%)
11.49
9.23
8.34
7.06
7.11
7.28
6.93
7.61
6.47
5.31
5.12
4.98
4.07
3.26
3.23
2.83
4.45
Return on Capital (%)
53.38
66.88
82.38
43.76
54
48.46
32.04
58.78
203.38
210.41
235.95
248.62
34.69
18.37
12.89
12.05
470.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
ST Debt
- -
81,450
LT Borrowings
- -
15,925
LT Finance Leases
- -
3,680
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
- -
3,121
Market Capitalization
58,255
60,596

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Total Current Assets
- -
382,363
Cash, Cash Equivalents & STI
- -
43,332
Accounts Receivable, Net
- -
234,307
Inventories
- -
68,838
Total Current Liabilities
- -
283,238
Payables & Accruals
- -
- -
ST Debt
- -
81,450
Deferred Revenue
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.82%
8.35%
5.9%
Free Cash Flow
627.68%
23.21%
30.73%
Net Income, GAAP
7.33%
0.68%
1.5%
Sales/Revenue/Turnover
9.94%
4.91%
-1.6%
Total Cash Common Dividend
10.35%
3.55%
-21.84%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
144,969
- -
- -
596,570
2024
- -
- -
- -
- -
584,508
2025
- -
- -
- -
- -
575,168

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.9
2024
- -
- -
- -
- -
2.26
2025
- -
- -
- -
- -
2.29

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.82
2024
- -
- -
- -
- -
0.87
2025
- -
- -
- -
- -
0.68
Similar Companies
Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS)
Arjo AB (publ) (ARJO-B.ST)
Dingdang Health Technology Group Ltd. (9886.HK)
CHC Healthcare Group (4164.TW)
Covetrus, Inc. (CVET)
Cardinal Health, Inc. (0HTG.L)
Business
Sinopharm Group Co. Ltd. Sinopharm Group Co. Ltd. engages in the wholesale and retail distribution of pharmaceutical products, medical devices, and healthcare items primarily in China. The company operates through key segments including pharmaceutical distribution, which supplies drugs such as antibiotics, biological products, and Chinese herbal medicines to hospitals, clinics, distributors, and retail pharmacies while providing logistics and value-added services; medical devices distribution, encompassing installation, maintenance, and sales of equipment; retail pharmacy, managing and franchising a nationwide network of drug stores; and other businesses involving laboratory supplies, chemical reagents manufacturing, property management, and pharmaceutical production. It also offers information technology, import-export, consulting, and exhibition services, with operations centered in China and exports worldwide. Founded in 2003 as a subsidiary of China National Pharmaceutical Group Co. Ltd., a state-owned enterprise established in 1998 and headquartered at 20 Zhichun Road, Haidian District, Beijing, China, Sinopharm Group Co. Ltd. maintains its principal operations from Shanghai. The company serves diverse customers including healthcare providers, manufacturers, and consumers through an extensive supply chain focused on life and health industries. Recent developments include a deep strategic cooperation agreement signed on December 13, 2024, with China Biopharmaceutical to integrate resources in retail pharmacy, national university pharmacy, and professional services, aiming to build a nationwide off-hospital market network and enhance patient access. In December 2024, its subsidiary Hupan Pharmaceutical entered a $1.5 million sales agreement with Sinopharm Holding Hubei New Special Medicine Co., Ltd. for essential medicine supply following prior logistics partnerships. Additionally, in April 2023, it formed a cooperation pact with Pfizer to seek approvals for 12 drugs in China by 2025, bolstering its portfolio amid ongoing expansions in distribution and manufacturing.

Company News

APIChatGPT

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDF) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

  • defenseworld.net

    Sinopharm Group (OTCMKTS:SHTDF) Stock Price Passes Above 50 Day Moving Average – Time to Sell?